Shares of Viatris Inc. VTRS slipped 1.07% to $9.24 Wednesday, on what proved to be an all-around mixed trading session for ...

NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN VIATRIS INC. (VTRS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its ...

Medication company Viatris (NASDAQ:VTRS) in Q4 CY2024, with sales falling 8.1% year on year to $3.53 billion. The company’s ...

Barclays 27th Annual Global Healthcare Conference Call March 11, 2025 2:00 PM ETCompany ParticipantsScott Smith - Chief ...

Viatris (VTRS, Financials) shares dropped about 15% in pre-market trading after the company reported weaker-than-expected ...

Viatris launches review, plans share buybacks. CEO outlines strategy for cost structure and remediation efforts.

Viatris forecast annual revenue and profit below Wall Street estimates on Thursday, mainly due to a worse-than-feared hit to sales from import restrictions on the drugmaker's manufacturing plant in ...

Viatris missed Q4 estimates with an 8% revenue decline. 2025 guidance falls short as FDA import alert hits sales. Share ...